Genomma Lab Internacional, S.A.B. De C.V. Cash Dividend
October 26, 2022 at 07:37 pm EDT
Share
Genomma LabInternacional, S.A.B. de C.V. declaring a cash dividend of MXN 0.381679389 per share on its common stock representing a total amount of $400,000,000.00 M.N. (four hundred million pesos 00/100 National Currency), payable to shareholders of record at the close of business on November 11, 2022. This amount is based on the total LABB shares currently in circulation.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. 
